False-negative 123I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease

Endocrine-Related Cancer

Volumn 19, Issue 1, 2012, Pages 83-93

  Fonte, Jay S ^a,c   Robles, Jeremyjones F ^a,c   Chen, Clara C ^b   Reynolds, James ^b   Whatley, Millie ^b   Ling, Alexander ^b   Mercado Asis, Leilani B ^c   Adams, Karen T ^a   Martucci, Victoria ^a   Fojo, Tito ^d   Pacak, Karel ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF SANTO TOMAS HOSPITAL   (Philippines)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ADRENALIN; CATECHOLAMINE; DOPA; DOPAMINE; FLUORODEOXYGLUCOSE F 18; METADRENALIN; NORADRENALIN; NORMETADRENALIN; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE SUBUNIT B; UNCLASSIFIED DRUG; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; PROTEIN RET; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; RET PROTEIN, HUMAN; SDHB PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CATECHOLAMINE BLOOD LEVEL; CATECHOLAMINE EXCRETION; CAUSE OF DEATH; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; METASTASIS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR VOLUME; ADRENAL TUMOR; BLOOD; GENETICS; LABORATORY DIAGNOSIS; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; FALSE NEGATIVE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; METANEPHRINE; MIDDLE AGED; MUTATION; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-RET; RADIOPHARMACEUTICALS; SUCCINATE DEHYDROGENASE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 84860909317     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0243     Document Type: Article

References (43)

1. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Murat A et al. 2005 Genetic testing in pheochromocytoma or functional paraganglioma. Journal of Clinical Oncology 23 8812-8818. (doi:10.1200/JCO.2005.03.1484)
2. Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, Bertagna X, Schlumberger M, Jeunemaitre X, Gimenez-Roqueplo AP et al. 2007 Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. Journal of Clinical Endocrinology and Metabolism 92 3822-3828. (doi:10.1210/jc.2007-0709)
3. 123I- metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clinical Endocrinology 69 181-188. (doi:10.1111/j.1365-2265.2008.03256.x)
4. Bomanji J, Levison DA, Flatman WD, Horne T, Bouloux PM, Ross G, Britton KE & Besser GM 1987 Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: a histopathological comparison. Journal of Nuclear Medicine 28 973-978. (Pubitemid 17086816)
5. Bravo EL & Tagle R 2003 Pheochromocytoma: state-of-the-art and future prospective. Endocrine Reviews 24 539-553. (doi:10.1210/er.2002-0013)
6. Brouwers FM, Einsenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM & Pacak K 2006 High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. Journal of Clinical Endocrinology and Metabolism 91 4505-4509. (doi:10.1210/jc.2006-0423)
7. Burnichon N, Rohmer V, Amar L, Herman P, Leboulleux S, Darrouzet V, Niccoli P, Gaillard D, Chabrier G, Chabolle F et al. 2009 The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. Journal of Clinical Endocrinology and Metabolism 94 2817-2827. (doi:10.1210/jc.2008-2504)
8. Castellani MR, Seghezzi S, Chiesa C, Aliberti GL, Maccauro M, Seregni E, Orunesu E, Luksch R & Bombardieri E 2010 (131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging 54 100-113.
9. Comino-Méndez I, Gracia-Aznárez FJ, Schiavi F, Landa I, Leandro-García LJ, Letón R, Honrado E, Ramos-Medina R, Caronia D, Pita G et al. 2011 Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nature Genetics 43 663-667. (doi:10.1038/ng.861)
10. DeLellis RA, Lloyd RV, Heitz PU & Eng C 2004 In, World Health Organization 2004 WHO Classification of Tumours, Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press.
11. Eisenhofer G 2001 The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacology and Therapeutics 91 35-62. (doi:10.1016/S0163-7258(01)00144-9)
12. Eisenhofer G, Lenders JW, Timmers H, Mannelli M, Grebe SK, Hofbauer LC, Bornstein SR, Tiebel O, Adams K, Bratslavsky G et al. 2011 Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clinical Chemistry 57 411-420. (doi:10.1373/clinchem.2010.153320)
13. Erlic Z, Rybicki L, Peczkowska M, Golcher H, Kann PH, Brauckhoff M, Müssig K, Muresan M, Schäffler A, Reisch N et al. 2009 Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clinical Cancer Research 15 6378-6385. (doi:10.1158/1078-0432.CCR-09-1237)
14. Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, Jager PL, Elsinga PH, Dierckx RA, van der Wal JE et al. 2009 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computed tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. Journal of Clinical Endocrinology and Metabolism 94 3922-3930. (doi:10.1210/jc.2009-1054)
15. 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. Journal of Clinical Endocrinology and Metabolism 95 2800-2810. (doi:10.1210/jc.2009-2352)
16. Goldsmith SJ 2009 Update on nuclear medicine imaging of neuroendocrine tumors. Future Oncology 5 75-84. (doi:10.2217/14796694.5.1.75)
17. Goldstein RE, O'Neill JA Jr, Holcomb GW, Morgan WM, Neblett WW, Oates JA, Brown N, Nadeau J, Smith B, Page DL et al. 1999 Clinical experience over 48 years with pheochromocytoma. Annals of Surgery 229 755-766. (doi:10.1097/ 00000658-199906000-00001)
18. 131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. Journal of Clinical Oncology 27 4162-4168. (doi:10.1200/JCO.2008.21.3496)
19. van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP et al. 2001 [(123)I]Metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. Journal of Clinical Endocrinology and Metabolism 86 685-693. (doi:10.1210/jc.86.2.685)
20. Havekes B, Lai EW, Corssmit EPM, Romijn JA, Timmers HJLM & Pacak K 2008 Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. Quarterly Journal of Nuclear Medicine and Molecular Imaging 52 419-429.
21. Hensen EF & Bayley JP 2011 Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma. Familial Cancer 10 355-363. (doi:10.1007/s10689-010-9402-1)
22. Ilias I & Pacak K 2004 Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 89 479-491. (doi:10.1210/jc.2003-031091)
23. 131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 88 4083-4087. (doi:10.1210/jc.2003-030235)
24. 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. Journal of Clinical Endocrinology and Metabolism 95 2596-2606. (doi:10.1210/jc.2009-2604)
25. 18F]fluorodihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocrine-Related Cancer 16 255-265. (doi:10.1677/ERC-08-0229)
26. 111In-pentetreotide scintigraphy. Journal of Clinical Endocrinology and Metabolism 96 2779-2785. (doi:10.1210/jc.2011-0333)
27. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS & Eisenhofer G 2002 Biochemical diagnosis of pheochromocytoma: which test is best? Journal of the American Medical Association 287 1427-1434. (doi:10.1001/jama.287.11.1427)
28. 131I-MIBG): a comprehensive reviewof 116 reported patients. Journal of Endocrinological Investigation 20 648-658.
29. Maher ER & Eng C 2002 The pressure rises: update on the genetics of phaeochromocytoma. Human Molecular Genetics 11 2347-2354. (doi:10.1093/hmg/11. 20.2347)
30. Mannelli M, Castellano M, Schiavi F, Filetti S, Giacchè M, Mori L, Pignataro V, Bernini G, Giachè V, Bacca A et al. 2009 Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. Journal of Clinical Endocrinology and Metabolism 94 1541-1547. (doi:10.1210/jc.2008-2419)
31. Meyer-Rochow GY, Schembri GP & Benn DE 2010 The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (MIBG SPECT/CT) for the diagnosis of pheochromocytoma. Annals of Surgical Oncology 17 392-400. (doi:10.1245/s10434-009-0850-5)
32. 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 98 239-248. (doi:10.1002/cncr.11518)
33. Sawka AM, Jaeschke R, Singh RJ & Young WF Jr 2003 A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. Journal of Clinical Endocrinology and Metabolism 88 553-558. (doi:10.1210/jc.2002-021251)
34. Shulkin BL, Thompson NW, Shapiro B, Francis IR & Sisson JC 1999 Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 212 35-41. (Pubitemid 29302508)
35. Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM, Tobes MC, Beierwaltes WH & Thompson NW 1981 Scintigraphic localization of pheochromocytoma. New England Journal of Medicine 305 12-17. (doi:10.1056/NEJM198107023050103)
36. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ & Britton KE 1992 A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled metaiodobenzylguanidine (MIBG). Nuclear Medicine Communications 13 513-521. (doi:10.1097/00006231-199207000-00006)
37. Taïeb D, Sebag F, Hubbard JG, Mundler O, Henry JF & Conte-Devolx B 2004 Does iodine-131 meta-iodobenzylguanidine (MIBG) scintigraphy have an impact on the management of sporadic and familial phaeochromocytoma? Clinical Endocrinology 61 102-108. (doi:10.1111/j.1365-2265.2004.02077.x)
38. Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, Adams KT, Solis D, Lenders JW & Pacak K 2007a Superiority offluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. Journal of Clinical Oncology 25 2262-2269. (doi:10.1200/JCO.2006. 09.6297)
39. Timmers HJ, Kozupa A, Eisenhofer G, Raygada M, Adams KT, Solis D, Lenders JW & Pacak K 2007b Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. Journal of Clinical Endocrinology and Metabolism 92 779-786. (doi:10.1210/jc.2006-2315)
40. 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. Journal of Clinical Endocrinology and Metabolism 94 4757-4767. (doi:10.1210/jc.2009-1248)
41. 18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO). Clinical Endocrinology 71 11-17. (doi:10.1111/j.1365-2265.2008.03496.x)
42. Vaidyanathan G 2008 Meta-iodobenzylguanidine and analogues: chemistry and biology. Quarterly Journal of Nuclear Medicine and Molecular Imaging 52 351-368.
43. 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. Journal of Nuclear Medicine 50 1448-1454. (doi:10.2967/jnumed.108.058701)